Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8K3C

Nipah virus Attachment glycoprotein with 41-6 antibody fragment

Summary for 8K3C
Entry DOI10.2210/pdb8k3c/pdb
EMDB information36849
DescriptorLight chain of 41-6 Fab fragment, Heavy chain of 41-6 Fab fragments, Glycoprotein G (3 entities in total)
Functional Keywordsnipah virus, attachment glycoprotein, tetramer complex, neutralizing antibody, viral protein, viral protein-immune system complex, viral protein/immune system
Biological sourceHomo sapiens
More
Total number of polymer chains4
Total formula weight154038.86
Authors
Sun, M.M. (deposition date: 2023-07-15, release date: 2024-05-01, Last modification date: 2024-11-13)
Primary citationChen, L.,Sun, M.,Zhang, H.,Zhang, X.,Yao, Y.,Li, M.,Li, K.,Fan, P.,Zhang, H.,Qin, Y.,Zhang, Z.,Li, E.,Chen, Z.,Guan, W.,Li, S.,Yu, C.,Zhang, K.,Gong, R.,Chiu, S.
Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains.
Nat Commun, 15:2987-2987, 2024
Cited by
PubMed Abstract: Nipah virus (NiV) is a World Health Organization priority pathogen and there are currently no approved drugs for clinical immunotherapy. Through the use of a naïve human phage-displayed Fab library, two neutralizing antibodies (NiV41 and NiV42) targeting the NiV receptor binding protein (RBP) were identified. Following affinity maturation, antibodies derived from NiV41 display cross-reactivity against both NiV and Hendra virus (HeV), whereas the antibody based on NiV42 is only specific to NiV. Results of immunogenetic analysis reveal a correlation between the maturation of antibodies and their antiviral activity. In vivo testing of NiV41 and its mature form (41-6) show protective efficacy against a lethal NiV challenge in hamsters. Furthermore, a 2.88 Å Cryo-EM structure of the tetrameric RBP and antibody complex demonstrates that 41-6 blocks the receptor binding interface. These findings can be beneficial for the development of antiviral drugs and the design of vaccines with broad spectrum against henipaviruses.
PubMed: 38582870
DOI: 10.1038/s41467-024-47213-8
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.88 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon